Rare diseases

• 12/23/2024

  Trump’s Impact: Top Biotech Stocks to Buy Amid Industry Uncertainty

• 11/8/2024

  “Unlock Intellia Therapeutics’ 354% Upside Potential: A Gene-Editing Gem?”

• 11/3/2024

  Biogen’s Q3 Earnings Beat Expectations, Driven by Alzheimer’s Breakthrough

• 10/21/2024

  Pfizer Investment: Why I’m Bullish on the Pharma Giant

• 9/30/2024

  **Travere Therapeutics: Overcoming Challenges with Filspari’s Potential**

• 9/29/2024

  **2 High-Risk, High-Reward Stocks to Buy**